PBLS.US Parabilis Medicines, Inc. Common Stock
- Market cap
- USD 3.56B
- P/E
- -
- P/B
- 3.40x
- ROE
- -18.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PBLS.US undervalued?
Graham numberThe Graham number of Parabilis Medicines, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Parabilis Medicines, Inc. Common Stock fundamental analysis
No fundamental analysis for Parabilis Medicines, Inc. Common Stock yet.
Parabilis Medicines, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, wit…
Full company profileParabilis Medicines, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Parabilis Medicines, Inc. Common Stock annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | 3.02M |
| Operating Income | -126M | -152M | -204M |
| EBITDA | -114M | -142M | -201M |
| Net Income | -118M | -146M | -190M |
| EPS | -1.00 | -1.23 | -1.53 |
| Balance Sheet | |||
| Total Assets | 149M | 80.8M | 1.13B |
| Total Liabilities | 92.8M | 97.3M | 127M |
| Shareholders' Equity | 56.4M | -16.5M | 1.00B |
| Cash & Short-term Investments | 88.0M | 27.7M | 872M |
| Total Debt | 66.2M | 58.7M | 41.8M |
| Cash Flow | |||
| Operating Cash Flow | -104M | -124M | -125M |
| Capital Expenditure | 879K | 306K | 2.13M |
| Free Cash Flow | -104M | -124M | -127M |
| Ratios | |||
| ROE | -208.9% | - | -18.9% |
| ROA | -79.0% | -180.5% | -16.8% |
| Net Profit Margin | - | - | -6,289.6% |
| Debt to Equity | 1.17x | - | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Parabilis Medicines, Inc. Common Stock dividends
Parabilis Medicines, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Parabilis Medicines, Inc. Common Stock
- Insiders 7.08%
- Institutions 86.31%
- Public & others 6.61%
- Shares outstanding 124M
- Free float 83.8M
Top funds holding PBLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Health Sciences | 2.17M | 1.76% | 0.00% | Sep 2026 |
| HBM Healthcare Investments AG Ord | 1.19M | 0.97% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.12M | 0.91% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1,000K | 0.81% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 793K | 0.64% | -2.08% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 516K | 0.42% | +100.51% | Sep 2026 |
| Fidelity Growth Company Fund | 479K | 0.39% | 0.00% | Aug 2026 |
| JPMorgan Small Cap Growth A | 470K | 0.38% | -0.61% | Sep 2026 |
| Fidelity Select Biotechnology | 436K | 0.35% | +198.60% | Aug 2026 |
| Janus Henderson Global Life Sciences D | 376K | 0.30% | +6.27% | Sep 2026 |
| Janus Global Life Science AUSD | 373K | 0.30% | +19.31% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 370K | 0.30% | 0.00% | Jun 2026 |
| Janus Henderson Triton D | 367K | 0.30% | +90.74% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 351K | 0.28% | +8.08% | Aug 2026 |
| Fidelity Small Cap Growth | 320K | 0.26% | 0.00% | Aug 2026 |
| AB Small Cap Growth A | 316K | 0.26% | -2.51% | Sep 2026 |
| MFS New Discovery I | 272K | 0.22% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 230K | 0.19% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 224K | 0.18% | -0.38% | Oct 2026 |
| Janus Henderson Venture D | 224K | 0.18% | +91.14% | Sep 2026 |
Top institutions holding PBLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 28.9M | 23.40% | 0.00% | Jun 2026 |
| FMR Inc | 10.3M | 8.32% | 0.00% | Jun 2026 |
| ARCH VENTURE CORP | 6.41M | 5.19% | 0.00% | Jun 2026 |
| venBio Partners LLC | 5.27M | 4.26% | 0.00% | Jun 2026 |
| Alphabet Inc | 4.92M | 3.98% | 0.00% | Jun 2026 |
| Nextech Invest, Ltd. | 4.66M | 3.77% | 0.00% | Jun 2026 |
| Cormorant Asset Management, LLC | 4.62M | 3.73% | 0.00% | Jun 2026 |
| Regeneron Pharmaceuticals Inc | 4.17M | 3.37% | 0.00% | Sep 2026 |
| Siren, L.L.C. | 2.99M | 2.42% | 0.00% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 2.37M | 1.92% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 2.30M | 1.86% | 0.00% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 1.92M | 1.55% | 0.00% | Jun 2026 |
| Deerfield Management Co | 1.88M | 1.52% | 0.00% | Jun 2026 |
| General Catalyst Group Management, LLC | 1.60M | 1.29% | 0.00% | Jun 2026 |
| General Atlantic Llc | 1.54M | 1.24% | 0.00% | Sep 2026 |
| Soleus Capital Management, L.P. | 1.47M | 1.18% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.30M | 1.05% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.16M | 0.94% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.04M | 0.84% | 0.00% | Jun 2026 |
| Foresite Capital Management VI LLC | 999K | 0.81% | 0.00% | Jun 2026 |
Parabilis Medicines, Inc. Common Stock company profile
- Company name
- Parabilis Medicines, Inc. Common Stock
- Ticker
- PBLS.US
- Exchange
- USA Stocks
- Listed since
- Jun 10, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Fiscal year end
- December
- Address
- 30 Acorn Park Drive, Cambridge, MA, United States, 02140
- Phone
- (617) 945-9510
- Website
- parabilismed.com
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Parabilis Medicines, Inc. Common Stock management
10- Dr. Mathai Mammen M.D., Ph.D.CEO, President, Treasurer & Chairman · born 1967
- Ms. Teresa L. Jurgensen J.D.Executive VP, Secretary & General Counsel · born 1978
- Mr. John McGee Ph.D.Scientific Co-Founder, Executive Vice President & Head of Platform
- Mr. Thomas Rodolpho KotarakosChief Financial Officer · born 1982
- Dr. Rohin Mhatre Ph.D.Chief Technical Operations Officer · born 1965
- Ms. Kristen StantsChief People Officer · born 1973
- Dr. Jonathan Hurov Ph.D.Executive Vice President of Discovery Biology
- Ms. Marie Nguyen M.D.Senior VP & Head of Clinical Development
- Dr. Markus Haeberlein MSc, Ph.D.Executive Vice President of Discovery Science · born 1969
- Dr. Huei-in Ho Ph.D.Chief Business & Strategy Officer · born 1979